Phytoestrogen supplementation: a case report of male breast cancer

Dimitrakakis, Constantine; Gosselink, L; Gaki, V.; Bredakis, N.; Keramopoulos, A

doi:10.1097/00008469-200412000-00003

Cited by 10 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various herbal mixtures resulted in prostate cancer growth stimulatory activity, delayed type hypersensitivity, hypokalemia, hypokalemic hypochloremic metabolic alkalosis, hyponatremia and drug interaction 33,34,35,36,37,38,. Other reported adverse events included: development of male breast cancer after prolonged consumption of a phytoestrogen39, intraoperative haemorrhage following consumption of saw palmetto40 and severe bone marrow suppression associated with consumption of Selaginella doederleinii41 and Cantharanthus roseus42…”

Section: Resultsmentioning

confidence: 99%

Herbal therapy use by cancer patients: A literature review on case reports

Olaku

White

2011

European Journal of Cancer

136

114

View full text Add to dashboard Cite

Complementary and alternative medicine use is common among cancer patients. In many surveys, herbal medicines are among the most commonly used group of treatments. Herbal remedies are believed by the general public to be safe, cause less side effects and less likely to cause dependency.The authors performed a literature review to assess which herbal approaches have had associated cancer case reports and determine which of these have been studied in prospective research. Eighteen case reports of patients having apparent antitumour effects from herbal therapy and 21 case reports of toxic effects of herbs used by cancer patients were identified. Clinicaltrials.gov and MEDLINE (via PubMed) were searched for each of the herbal products identified in these reports. Clinical trials in cancer populations were identified for green tea extracts or compounds (n = 34), phytoestrogens (n=27), mistletoe (n =8), Ganoderma lucidum (n=1), Noni (n = 1) and Silymarin (n = 1). Daikenchuto, PC-SPES, Nyoshinsan/TJ and Saw palmetto have also been studied prospectively.In conclusion, some of the herbs with promising case report findings have undergone prospective clinical investigations but many others have either not yet been explored or the results have not been reported in English. Unconventional therapies, such as herbs and minerals, used in ancient medical traditions have led to the identification of active anticancer agents. Mechanisms to support prospective research with such approaches are discussed. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. We performed a literature review to assess which herbal approaches have had associated cancer case reports and determine which of these have been studied in prospective research. Keywords NIH Public Access MethodsWe conducted a search for all English language articles in MEDLINE We sought case reports of the use of herbal compounds by cancer patients. Case reports were classified as to whether the report described an apparent therapeutic benefit (i.e. antitumour response or symptomatic improvement) or rather an adverse effect following consumption of an herbal preparation.We searched MEDLINE via PubMed for reports of clinical trials using the names of the herbal interventions described in the case reports. Clinicaltrials.gov was searched to identify active or recently completed trials of the same interventions ResultsForty-three articles describing 71 individual case reports were identified that met the above criteria for inclusion. There were 18 case reports of patients having apparent anti-tumor effects from herbal therapy. (Table 1) ...

show abstract

Section: Resultsmentioning

confidence: 99%

Herbal therapy use by cancer patients: A literature review on case reports

Olaku

White

2011

European Journal of Cancer

136

114

View full text Add to dashboard Cite

show abstract

“…Moreover, there is an intense discussion in the scientific and even more so in the public community about the potential (benefits or detrimental) effects of plant-derived compounds that may affect the endocrine system, especially estrogen signaling pathways (Messina and Wood, 2008). Dimitrakakis et al (2004) reported adverse events included the development of male breast cancer after prolonged consumption of a phytoestrogen.…”

Section: Introductionmentioning

confidence: 99%

Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin

Gomes¹,

Cardoso²,

Varanda³

et al. 2011

Rev. bras. farmacogn.

View full text Add to dashboard Cite

Cancer constitutes the second main mortality cause in the world, after cardiovascular diseases. In spite of the progresses in the chemotherapeutics treatments, many patients fail chemotherapy, mainly because of side effects or multidrugs resistance, proving the need and importance of the research for new molecules with anticancer activity, more effective and with smaller adverse effects. Various compounds derived from plant secondary metabolites are commonly used in the chemotherapy against cancer and the natural products play an important role in the research for new molecules. Among several molecules of natural origin evaluated by MTT assay in murine tumor cell lines [breast (LM3) and lung (LP07)] the quinonamethide triterpenes tingenone and pristimerin showed marked cytotoxic activity presenting IC50 around 2 and 5 µM respectively. The structure-activity relationship suggests that rings A and B containing an α, ß-unsaturated carbonyl group are essential for the observed cytotoxic activity. The interaction between these positions and acetylcisteyne residues suggests a probable mechanism of action. The in vitro mutagenic activity was also evaluated by the Salmonella microsome assay (Ames test) for pristimerin and tingenone with and without metabolic activation (S9) in the strains TA98, TA97a, TA100 and TA102, none of which showed mutagenic potential in any strains. Estrogenic and anti-estrogenic activities were also studied by the e-screen assay in MCF-7 cells with negative results. The present data point to the importance of pristimerin and tingenone as representative of an emerging class of potential anticancer chemicals.

show abstract

“…Male breast carcinoma is promoted by genetic, environmental and hormonal factors [5][6][7][8][9][10][11]. A relationship between long-term androgen therapy and breast carcinoma in men is not sufficiently documented [12].…”

Section: Introductionmentioning

confidence: 99%

Breast cancer and long-term hormonal treatment of male hypogonadism

Mędraś

Filus

Jóźków

et al. 2006

Breast Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer in men is rare and its etiology is multifactorial. Androgens may promote the development of breast carcinoma in men though data on the subject is scarce. We observed 45 men with hypergonadotropic hypogonadism (aged 18-57) who received 250 mg of testosterone esters (Omnadren 250, Jelfa, Poland) every 3-4 weeks for 5-26 years. Seventeen of them were treated for more than 10 years. During the observation period breast cancer was diagnosed in 2 subjects (11% of the followed men). In one case it occurred after 11 years and in the other after 15 years of the therapy. We point to a possible association between long-term androgen replacement and a risk of breast cancer in men.

show abstract

Phytoestrogen supplementation: a case report of male breast cancer

Cited by 10 publications

References 15 publications

Herbal therapy use by cancer patients: A literature review on case reports

Herbal therapy use by cancer patients: A literature review on case reports

Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin

Breast cancer and long-term hormonal treatment of male hypogonadism

Contact Info

Product

Resources

About